 Long-term evaluation indobufen peripheral vascular disease Indobufen inhibitor platelets aggregation patients intermittent claudication due peripheral vascular disease Patients year patient indobufen ASA control group patients treatment authors means treadmill exercise test pain-free walking distance PFWD global walking distance GWD recovery time exercise treatment period patients claudicants claudicants diabetes short PFWD GWD Indobufen effective ASA PFWD GWD groups side effects indobufen cardiac morbidity mortality conclusion indobufen activity safety chronic treatment patients peripheral disease long periods side effects